The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
Open accessAbstract
5-Fluorouracil (5-FU) is a widely used drug for the therapy of cancer. However, the chemoresistance of tumor cells to 5-FU usually limits its clinical effectiveness. In this study, we explored the role of NLRP3 inflammasome in 5-FU resistance of oral squamous cell carcinoma (OSCC). The mRNA and protein expression levels of NLRP3, Caspase1 and IL-1β in resected OSCC specimens or cell lines were measured respectively by quantitative real time-PCR (qRT-PCR) and western blot. NLRP3 and Ki-67 expression in paraffin-embedded OSCC tissues was determined by immunohistochemistry. The correlation between 5-FU treatment and the expression and activation of NLRP3 inflammasome was further examined by evaluating NLRP3 and IL-1β expression in OSCC cell lines without or with NLRP3 knocked down. Cell viabilities of OSCC cells were determined by the MTT assay. Apoptosis and intracellular reactive oxygen species (ROS) of OSCC cells induced by 5-FU were measured by the flow cytometer. The carcinogen-induced tongue squamous carcinoma mice model was established by continuous oral administration of 4-nitroquinoline 1-oxide in wild-type BALB/c, Nlrp3 −/− and Caspase1 −/− mice. Tumor incidence were observed and tumor area were evaluated. In the clinical analysis, expression and activation of NLRP3 inflammasome was clearly increased in OSCC tissues of patients who received 5-FU-based chemotherapy. Multivariate Cox regression analysis revealed that this high expression was significantly correlated with tumor stage and differentiation, and was associated with poor prognosis. Moreover, 5-FU treatment increased expression and activation of NLRP3 inflammasome in OSCC cells in a cell culture system and xenograft mouse model. Silencing of NLRP3 expression significantly inhibited OSCC cell proliferation and enhanced 5-FU-induced apoptosis of OSCC cells. Further investigation showed that intracellular ROS induced by 5-FU promoted the expression and activation of NLRP3 inflammasome and increased the production of interleukin (IL)-1β, which then mediated the chemoresistance. With the carcinogen-induced OSCC model, we found less and later tumor incidence in Nlrp3 −/− and Caspase1 −/− mice than wild-type mice. And greater decrease of tumor area was observed in the gene deficient mice treated with 5-FU. Our findings suggest that NLRP3 inflammasome promoted 5-FU resistance of OSCC both in vitro and in vivo, and targeting the ROS/NLRP3 inflammasome/IL-1β signaling pathway may help 5-FU-based adjuvant chemotherapy of OSCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618
Inflammasomes in carcinogenesis and anticancer immune responses
Zitvogel, L., Kepp, O., Galluzzi, L., & Kroemer, G. (2012) · Nature Immunology · doi:10.1038/ni.2224 · Cited by 593
Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells
WANG, Y., KONG, H., ZENG, X., LIU, W., WANG, Z., YAN, X., WANG, H., & XIE, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4569 · Cited by 186
Self-citationNissinen, L., Farshchian, M., Riihilä, P., & Kähäri, V.-M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2457-z · Cited by 80
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Diverging inflammasome signals in tumorigenesis and potential targeting
Karki, R., & Kanneganti, T.-D. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0123-y · Cited by 641
Role of the NLRP3 inflammasome in cancer
Moossavi, M., Parsamanesh, N., Bahrami, A., Atkin, S. L., & Sahebkar, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0900-3 · Cited by 417
Lian, M. Q., Chng, W. H., Liang, J., Yeo, H. Q., Lee, C. K., Belaid, M., Tollemeto, M., Wacker, M. G., Czarny, B., & Pastorin, G. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12283 · Cited by 388
Metadata
- Authors
- Feng, X., Luo, Q., Zhang, H., Wang, H., Chen, W., Meng, G., & Chen, F.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2017-06-21
- Volume
- 36
- Issue
- 1
- Pages
- 81-81
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2660411982
- Cited by
- 170
- References
- 7
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. https://app.cochat.ai/papers/10.1186/s13046-017-0553-x
- The paper
- Feng, X., Luo, Q., Zhang, H., Wang, H., Chen, W., Meng, G., & Chen, F. (2017). The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-017-0553-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.